Systemic lupus erythematosus

Nature Reviews Drug Discovery

Volumn 8, Issue 2, 2009, Pages 103-104

  Wentworth, James ^a   Davies, Clare ^a  

^a Immunology and Inflammation Team   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ATACICEPT; AZATHIOPRINE; BELIMUMAB; CNTO 136; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EDRATIDE; EPRATUZUMAB; HYDROXYCHLOROQUINE; IMMU 106; IMMUNOSUPPRESSIVE AGENT; IPP 201101; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PRASTERONE; PREDNISONE; RG 2077; RITUXIMAB; SALBUTAMOL SULFATE; TACROLIMUS; UNCLASSIFIED DRUG; VELTUZUMAB;

ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; EPIDEMIOLOGICAL DATA; HUMAN; INDIVIDUALIZATION; LEUKOENCEPHALOPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; OFF LABEL DRUG USE; PATIENT CARE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; UNITED STATES;

EID: 59349117999     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2743     Document Type: Article

References (4)

1. Lupus Foundation of America (LFA). Introduction to Lupus. LFA web site [online], (2008).
2. Helmick, C. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58, 15-25 (2008).
3. Genentech. Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus. Genentech web site [online], (2008).
4. FDA. FDA Warns of Safety Concern Regarding Rituxan in New Patient Population. FDA web site [online], (2006).